Stem Cell Therapy for Knees: Cost, Success Rates, and How It Compares to Surgery

A knee stem cell procedure costs between $3,000 and $25,000 or more in the United States, depending mostly on the cell type: bone marrow aspirate concentrate (BMAC) runs $3,000 to $8,000, adipose-derived stromal vascular fraction (SVF) $4,000 to $12,000, and culture-expanded mesenchymal stem cells $10,000 to $25,000+, usually abroad. No major U.S. insurance carrier covers it for knee osteoarthritis, and results depend more on how advanced your arthritis is than on how much you pay.

Knee pain that does not respond to physical therapy or anti-inflammatory medication puts a lot of people in a difficult position. Surgery feels drastic. Doing nothing feels like giving up. Stem cell therapy sits in between, promising regeneration rather than replacement. But the marketing has outrun the science in several ways, and knowing the difference matters before you spend thousands of dollars.

The sections below set out what the evidence shows, what each type of stem cell product costs, how success rates break down by disease severity, and when this treatment is and is not a reasonable choice. For a broader look at regenerative medicine options, see our Stem Cell Therapy Guide and Osteoarthritis Treatment Guide.

How Much Does a Knee Stem Cell Procedure Cost?

Stem cell injections for the knee cost $3,000 to $25,000 or more per treatment in the U.S., and the cell product is the biggest single driver of price. Same-day procedures that use your own bone marrow or fat sit at the lower end. Lab-grown, culture-expanded cells sit at the top, because U.S. rules push that work into clinical trials or clinics in Mexico, Panama and the Caribbean.

• Bone marrow aspirate concentrate (BMAC): $3,000 to $8,000 per treatment.
• Adipose-derived SVF: $4,000 to $10,000 with mechanical processing, and $6,000 to $12,000 with enzymatic processing.
• Amniotic and umbilical cord products: $2,500 to $6,000, although testing shows they rarely contain live cells.
• Culture-expanded MSCs: $10,000 to $25,000+, often bundled with travel and accommodation.

The price usually covers the consultation, ultrasound or fluoroscopy guidance, the cell harvest or product, and the injection. PRP add-ons, integration therapy and physical therapy protocols may add $500 to $2,000. Treating both knees, repeat injections and a second set of imaging all push the total higher, so ask for a written, itemized quote per knee before you book. The full table is under Cost Breakdown and What You Are Paying For.

Types of Stem Cell Products Used for Knees

Not all products marketed as “stem cell therapy” contain the same thing, and the differences matter clinically and financially. Clinicians and clinics also use several names for the same idea: stem cell injections, mesenchymal stem cell (MSC) therapy, mesenchymal stromal cells, orthobiologics, cellular therapy and regenerative injections.

Bone Marrow Aspirate Concentrate (BMAC)

BMAC is drawn from your iliac crest (hip bone), spun down in a centrifuge, and injected into the knee during the same visit. The concentrate contains mesenchymal stem cells (MSCs), platelets, and growth factors. Cell counts vary considerably by patient age and health status. This is the most studied autologous (your own cells) approach and is performed in a single-day outpatient procedure.

Cost range: $3,000 to $8,000 per treatment. The harvest procedure adds time and a second puncture site, which is why pricing sits above PRP but below culture-expanded options.

Adipose-Derived Stromal Vascular Fraction (SVF)

Fat tissue harvested via mini-liposuction is enzymatically or mechanically processed to isolate the SVF, which contains MSCs, pericytes, endothelial progenitor cells, and growth factors. Adipose tissue yields higher raw MSC numbers than bone marrow in most patients. Same-day procedures are possible with mechanical processing; enzymatic processing technically requires FDA oversight as a more-than-minimally-manipulated cell product. The FDA’s consumer guidance lists stromal vascular fraction among the regenerative products that need FDA approval before they can be marketed, so ask any clinic how its process fits those rules.

Cost range: $4,000 to $10,000 with mechanical processing, and $6,000 to $12,000 with enzymatic processing. The mini-liposuction step adds procedural complexity and cost compared to BMAC.

Culture-Expanded MSCs

Some clinics (primarily outside the U.S.) take bone marrow or adipose cells, culture them in a lab for several weeks to multiply the cell count, then cryopreserve and ship them for injection. This produces far higher cell doses (50-200 million cells vs. a few thousand to tens of thousands in BMAC). In the United States, culture-expanded MSCs require FDA IND approval for clinical use, which is why most offering clinics operate in Mexico, Panama, or the Cayman Islands.

Cost range: $10,000 to $25,000+, often bundled with travel and accommodation. Our look at stem cell therapy in Mexico covers what that travel adds in cost and risk.

Amniotic and Umbilical Cord Products

These allogeneic products are derived from placental tissue, amniotic membrane, or Wharton’s jelly in umbilical cords. They are widely marketed as containing live stem cells. Independent laboratory testing funded by the FDA and academic centers has repeatedly found that commercial amniotic and umbilical cord products contain few to no viable cells after processing and cryopreservation. What remains are growth factors, cytokines, and extracellular matrix proteins, which may have value but are not “stem cells” in any meaningful functional sense.

Cost range: $2,500 to $6,000. The scientific basis for the premium over PRP is questionable based on current evidence. Cell-free products sold as exosome therapy raise the same question and sit under the same FDA warning.

What Happens During a Knee Stem Cell Procedure?

A same-day BMAC or SVF knee procedure is an outpatient visit that usually takes a few hours from harvest to injection. Culture-expanded treatments split the harvest and the injection across separate trips, weeks apart. The typical sequence looks like this:

1. Consultation and imaging. A physician reviews a recent X-ray or MRI to assign a Kellgren-Lawrence grade and to rule out problems such as a mechanical meniscus tear or inflammatory arthritis.
2. Harvest. Bone marrow is aspirated from the back of the hip under local anesthetic, or fat is removed from the abdomen or flank with a small cannula.
3. Processing. The sample is concentrated in a centrifuge or processed mechanically on site, usually while you wait in the clinic.
4. Image-guided injection. The concentrate is placed into the knee joint under ultrasound or fluoroscopy so it reaches the joint space rather than surrounding tissue.
5. Recovery. Most patients have 1 to 3 days of downtime and return to full activity in 2 to 4 weeks, often with a guided physical therapy plan.

The procedure is usually performed by an orthopedic surgeon, a sports medicine physician, or a physical medicine and rehabilitation (PM&R) physician who uses musculoskeletal ultrasound. Soreness at the harvest site and a temporary flare of knee swelling are the most commonly reported side effects in published trials.

What the Evidence Shows

Three key clinical studies define what we reasonably know about stem cell injections for knee osteoarthritis.

Shapiro et al., 2017 (American Journal of Sports Medicine, N=25 RCT): This was one of the first randomized, single-blind, placebo-controlled trials of intra-articular BMAC in knee OA. Each of the 25 patients had arthritis in both knees, received BMAC in one knee and saline placebo in the other, and was followed for 6 months. Pain fell significantly in both knees, with no statistically significant difference between BMAC and placebo, according to the trial report on PubMed. The study highlighted the substantial placebo effect in knee injection trials and the need for larger, controlled studies.

Pers et al., 2016 (STEM CELLS Translational Medicine, N=18): A phase I dose-escalation study of autologous, culture-expanded adipose-derived stromal cells (ASCs) in severe knee OA, with low (2 million), medium (10 million) and high (50 million) cell doses. After 6 months the procedure was judged safe, no serious adverse events were reported, and four patients had transient knee pain and swelling, according to the published abstract. Pain and function improved as secondary outcomes. Limitations include the small sample size and absence of a control group.

Vega et al., 2015 (Transplantation, N=30 RCT): Compared allogeneic bone marrow-derived MSCs to hyaluronic acid in knee OA. The MSC group showed significantly greater improvements in pain, function, and MRI-measured cartilage quality at 12 months. This is one of the stronger early RCTs, though still limited by sample size. The Vega trial used 40 million donor cells against a single 60 mg hyaluronic acid injection and measured cartilage with quantitative T2 mapping.

Pooled reviews tell a similar story. A 2021 meta-analysis in the American Journal of Sports Medicine of ten studies and 472 patients found that a single BMAC or SVF injection improved knee symptoms at short-term follow-up, while warning that preparation methods varied widely and that the results should be read with caution.

Professional guidelines are more cautious than clinic marketing. The 2019 American College of Rheumatology and Arthritis Foundation guideline, led by Sharon Kolasinski, strongly recommends against stem cell injections for knee and hip osteoarthritis because preparations and techniques are not standardized, according to Kolasinski et al. (2020).

The honest summary: the evidence base is encouraging but not conclusive. Most studies are small, short-term, and lack rigorous placebo controls. Larger phase III trials are ongoing and can be tracked on ClinicalTrials.gov. Stem cell therapy for knees is not experimental in the sense that it has no basis, but it is not established in the sense that major medical societies recommend it as standard of care.

Success Rates by Kellgren-Lawrence Grade

Kellgren-Lawrence (KL) grading is the standard radiographic scale for osteoarthritis severity, from Grade I (minor) to Grade IV (severe bone-on-bone). Where you fall on this scale is probably the single most predictive factor for whether stem cell therapy will help you.

KL Grade	Description	Expected Improvement Rate	Appropriate Candidate?
Grade I	Possible osteophytes, no joint space narrowing	60-80% symptom improvement	Yes, strong candidate
Grade II	Definite osteophytes, possible narrowing	60-80% symptom improvement	Yes, good candidate
Grade III	Multiple osteophytes, definite narrowing, some sclerosis	40-60% symptom improvement	Reasonable candidate with realistic expectations
Grade IV	Large osteophytes, severe narrowing, bone-on-bone	Limited; 20-30% at best	Poor candidate; surgery often more appropriate

“Improvement” here refers to clinically meaningful reductions in KOOS (Knee Injury and Osteoarthritis Outcome Score) pain and function subscales, typically defined as a 10-point or greater improvement. It does not mean cartilage regrowth, which is rarely demonstrated on follow-up MRI in most clinical studies.

What Does “Success” Actually Mean?

Clinics advertising “80% success rates” are usually measuring patient-reported satisfaction or pain scores at 3-6 months, not MRI-confirmed cartilage regeneration. These are two very different things.

The most commonly used outcome measures in stem cell knee trials are KOOS subscales (pain, symptoms, activities of daily living, sport/recreation, quality of life) and VAS pain scores. A meaningful response is generally defined as a 30-50% reduction in pain scores maintained at 12 months. A minority of studies report MRI findings, and among those, improvements in cartilage thickness or T2 mapping are modest and not universal.

Duration of benefit is another open question. Studies following patients past 24 months are few. The working clinical assumption is that benefits may last 1-3 years in good responders, after which retreatment may be considered. No good predictors of durability exist yet.

Cost Breakdown and What You Are Paying For

Stem cell knee injections are not covered by any major U.S. insurance carrier for osteoarthritis or sports injuries. The full cost comes out of pocket. Here is what the pricing typically includes.

Product Type	Cost Range	Cell Source	Same-Day Procedure	FDA Status
BMAC	$3,000-$8,000	Patient (autologous)	Yes	Minimal manipulation (compliant)
Adipose SVF (mechanical)	$4,000-$10,000	Patient (autologous)	Yes	Minimal manipulation claimed; FDA lists SVF among unapproved products
Adipose SVF (enzymatic)	$6,000-$12,000	Patient (autologous)	No	Requires IND under FDA rules
Amniotic/Umbilical products	$2,500-$6,000	Donor (allogeneic)	Yes	Regulated as biologics; enforcement varies
Culture-Expanded MSCs	$10,000-$25,000+	Patient or donor	No (travel required)	Requires IND in U.S.; often done abroad

Cost components typically include the consultation, imaging (ultrasound or fluoroscopy for injection guidance), the cell harvest or product acquisition, the injection itself, and sometimes a follow-up visit. Integration therapy, physical therapy protocols, or PRP add-ons may add $500-$2,000 more.

Why Do Knee Stem Cell Prices Vary So Much Between Clinics?

Prices for the same named procedure differ because clinics bundle different things. One quote may cover a single knee with ultrasound guidance and one follow-up visit, while another covers both knees, an MRI and a PRP booster months later. Cell processing equipment, the physician’s specialty, local rents and whether a clinic sells multi-session packages all move the number.

Compare quotes line by line. Ask what cell product is used, how it is processed, whether the price is per knee, whether imaging guidance is included, and what a repeat injection would cost. A clinic that cannot answer those questions in writing is hard to compare fairly.

Does Insurance or Medicare Pay for Any of It?

Insurance does not pay for the stem cell injection itself for knee osteoarthritis, and Medicare does not cover it either. Some plans may still cover separate pieces, such as an office visit with an orthopedic specialist or a diagnostic X-ray ordered before any regenerative treatment is discussed. Health savings account (HSA) or flexible spending account (FSA) eligibility depends on your plan administrator, so check before you pay.

Is a Knee Stem Cell Procedure Cheaper Abroad?

The sticker price for culture-expanded cells in Mexico, Panama or the Cayman Islands sits at the top of the range, $10,000 to $25,000+, and travel, lodging and any follow-up care at home come on top. Cheaper overseas same-day procedures exist, but cell counts, lab standards and complication handling are harder to verify across borders, and U.S. physicians may be reluctant to manage problems from treatment they did not perform.

Is Stem Cell Therapy for Knees FDA Approved?

No stem cell product is FDA approved for knee osteoarthritis or any other orthopedic condition. The FDA states that regenerative medicine therapies have not been approved for osteoarthritis, knee pain, tendonitis or similar conditions, and that products such as stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton’s jelly and exosomes need FDA approval before they can be marketed, according to its patient and consumer information on regenerative medicine therapies.

BMAC sits in a different regulatory position. Because bone marrow is harvested and returned to the same patient during one procedure with minimal processing, it is generally offered under the exception for minimally manipulated tissue rather than as a licensed drug. That status explains why it is widely available in the U.S. It does not mean the FDA has reviewed it for effectiveness in knee arthritis.

The FDA has received reports of infections, blindness, tumor formation and other serious harm from unapproved regenerative products, mostly in uses far from the knee. Our explainer on which stem cell products are FDA approved covers the blood-forming cord blood products that are licensed, and why they do not apply here.

Stem Cell Therapy vs. Knee Replacement Surgery

Total knee replacement (TKR) is one of the most performed elective surgeries in the U.S., with roughly 700,000 procedures annually. It is effective for Grade IV disease, with 90% of patients reporting significant pain relief and functional improvement at 10 years. But it comes with real trade-offs.

Factor	Stem Cell Injection	Total Knee Replacement
Cost (out-of-pocket)	$3,000-$25,000	$30,000-$50,000 (with insurance); $35,000-$70,000 without
Recovery time	1-3 days downtime; full activity in 2-4 weeks	6-12 weeks limited; full recovery 3-6 months
Efficacy in Grade IV OA	Limited (20-30%)	High (85-90%)
Efficacy in Grade I-II OA	Good (60-80%)	Not indicated (overkill)
Reversibility	Reversible; can still have surgery later	Permanent structural change
Implant lifespan	N/A	15-20 years; revision needed eventually
Insurance coverage	None	Yes, under Medicare/most plans

The key insight is that stem cell therapy and knee replacement are not competing for the same patients. Grade I-III patients are not typically candidates for TKR, so stem cell therapy fills a gap where surgery is not yet indicated but pain is significant. Grade IV patients with bone-on-bone arthritis are unlikely to get adequate relief from stem cell injections.

Partial knee replacement (unicompartmental arthroplasty), high tibial osteotomy and arthroscopic cartilage procedures sit between injections and a full replacement for selected patients. An orthopedic surgeon can tell you whether any of those fit your X-ray before you price out a cash-pay injection.

Stem Cell Therapy vs. PRP and Other Knee Injections

Stem cell injections are one of several injection options for knee osteoarthritis, and most patients try cheaper, insurance-covered injections first. Platelet-rich plasma (PRP) is the closest relative: it uses a concentrate of your own blood platelets and growth factors, contains no stem cells, and is priced below BMAC. Prolotherapy injects an irritant solution, usually dextrose, to provoke a healing response in ligaments and the joint.

Injection	What Is Injected	Typical Coverage	Where It Usually Fits
Corticosteroid	Anti-inflammatory steroid	Usually covered by insurance	Short-term relief of a painful flare
Hyaluronic acid (viscosupplementation)	Lubricating gel similar to joint fluid	Often covered; plan rules vary	Mild to moderate OA after other care
Prolotherapy	Dextrose or other irritant solution	Usually cash pay	Ligament laxity and mild OA
PRP	Concentrated platelets from your blood	Usually cash pay	Mild to moderate OA; lower cost than cell therapy
BMAC or SVF	Concentrated cells and growth factors from marrow or fat	Cash pay	KL Grade I-III OA after conservative care fails

Head-to-head studies comparing BMAC with PRP or hyaluronic acid are few and small, and several have not shown a clear advantage for cell therapy. If cost matters, ask whether PRP for knee osteoarthritis is a reasonable first step for your grade. Our comparison of PRP vs. stem cell therapy walks through the trade-offs, and the prolotherapy treatment guide covers the dextrose option.

Who Is a Good Candidate?

Good candidates share several characteristics: KL Grade I-III osteoarthritis confirmed by X-ray or MRI; persistent pain and functional limitation despite 3-6 months of physical therapy and anti-inflammatory treatment; BMI below 35 (higher BMI is associated with worse outcomes); no active infection or inflammatory arthritis (rheumatoid, psoriatic); and realistic expectations about outcomes.

Age matters less than joint condition. A 65-year-old with Grade II OA may respond better than a 45-year-old with Grade IV disease. Athletes with focal cartilage defects rather than diffuse OA may also be reasonable candidates, though this is a different clinical indication with its own evidence base. Our overview of knee osteoarthritis explains how the grades are assigned.

Who Is Not a Good Candidate?

Patients with Grade IV bone-on-bone arthritis and significant varus or valgus deformity are unlikely to benefit meaningfully. Active cancer, blood disorders, or immunosuppressive therapy are contraindications. Patients with active joint infection, inflammatory arthritis flares, or clotting disorders should not proceed. Anyone expecting certain cartilage regeneration should recalibrate expectations before spending this kind of money.

How to Find and Vet a Knee Stem Cell Clinic

Start with the physician, not the product. A well run clinic is led by a board-certified orthopedic surgeon, sports medicine physician or PM&R physician who examines your knee, reviews your imaging and tells you plainly when a different treatment fits better. You can compare stem cell therapy clinics across the U.S. by location and services, then narrow to a state such as Florida or California.

Questions worth asking at the consultation:

• What cell product will be injected, and how is it harvested and processed?
• Is the quoted price per knee, and does it include imaging guidance and follow-up?
• What KL grade is my knee, and what results do you see in patients at that grade?
• How do you track outcomes, and how often do patients report no meaningful benefit?
• Is this product being studied in a clinical trial under FDA oversight, and if not, why not?

Regenerated.com is free for patients. Listing order in the directory is not paid ranking, Featured slots are clearly labeled and capped, and Verified means a clinic completed our credential checks, not that it spent money. Inclusion in the directory is not an endorsement, so use the listings as a starting point for the questions above. The guide to Featured, Verified and organic listings explains each label in detail.

For the treatment itself, the stem cell therapy treatment guide covers mechanisms and other uses, and the osteoarthritis treatment guide sets stem cells beside exercise therapy, weight management, bracing and medication.

Red Flags in Stem Cell Marketing

Be skeptical of any clinic that guarantees cartilage regrowth based on their injection. Be skeptical of vague descriptions like “millions of stem cells” without specifying cell type, viability, or sourcing. Be skeptical of pressure to purchase package deals of 3-5 sessions without a single-treatment trial first. Be skeptical of before-and-after MRI images shown without objective radiologist reports.

Legitimate regenerative medicine clinics will discuss failure rates openly, recommend imaging-guided injection, provide written informed consent covering all risks and the experimental status of the treatment, and not pressure you into a decision at the first consultation.

The Bottom Line

Stem cell injections for knee osteoarthritis occupy a legitimate but imprecisely defined clinical space. The biology is sound, early clinical results are promising for the right patients, and for Grade I-III disease the risk-to-benefit profile is reasonable. The cost is high, the evidence is not yet at the level that justifies broad adoption, and the marketing around certain products (particularly amniotic and umbilical cord products) is significantly ahead of the science.

A knee stem cell procedure costs $3,000 to $25,000 or more, paid out of pocket, so the decision deserves the same scrutiny as surgery. If you have moderate knee OA that has not responded to conservative care, and you have realistic expectations and budget for the cost, BMAC or adipose SVF from a reputable clinic is a defensible choice. If you have severe Grade IV disease and are hoping to avoid a knee replacement, this is probably not the solution. Talk to an orthopedic surgeon and a regenerative medicine specialist together before deciding.

---

Related Reading

• Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis
• Osteoarthritis: What It Is, Why It Progresses, and How Regenerative Medicine Is Changing Treatment
• Stem Cell Therapy: Types, Evidence, Cost, Risks, and What You Need to Know

Frequently Asked Questions

How much does stem cell therapy for the knee cost?

A knee stem cell procedure costs $3,000 to $25,000 or more in the U.S., depending on the cell type and processing. Bone marrow aspirate concentrate (BMAC) runs $3,000 to $8,000, adipose SVF $4,000 to $12,000, amniotic or umbilical products $2,500 to $6,000, and culture-expanded MSCs $10,000 to $25,000 and up, usually abroad. Same-day procedures cost less than those needing lab expansion and travel. Ask whether a quote is per knee and includes imaging guidance.

Does stem cell therapy for the knee actually work?

The evidence is encouraging but not conclusive, and it comes mainly from small, short-term studies. Shapiro et al. (2017) found no significant difference between BMAC and saline placebo at 6 months, while Vega et al. (2015) found greater improvement in pain, function and MRI-measured cartilage quality with donor MSCs than with hyaluronic acid. The American College of Rheumatology strongly recommends against stem cell injections for knee osteoarthritis. Reported improvement means lower pain scores, not cartilage regrowth.

How do success rates depend on how severe my arthritis is?

Outcomes track closely with Kellgren-Lawrence grade, which a physician assigns from your X-ray. The ranges summarized in the success-rate table are roughly 60 to 80 percent symptom improvement for Grade I and II, 40 to 60 percent for Grade III, and limited results of 20 to 30 percent at best for Grade IV. For Grade I to III disease the risk-to-benefit profile is reasonable. For bone-on-bone Grade IV arthritis, knee replacement is usually the more appropriate option.

Is it covered by insurance?

No. Stem cell knee injections are not covered by any major U.S. insurance carrier for osteoarthritis or sports injuries, and Medicare does not cover them either, so patients pay the full $3,000 to $25,000+ out of pocket. Some plans may still cover a specialist visit or diagnostic X-ray before treatment. Whether HSA or FSA funds can be used depends on your plan administrator, so confirm eligibility in writing before you pay a deposit.

How long do the results last?

Nobody knows precisely, because few studies follow patients past 24 months. Most trials measure outcomes at 6 to 12 months. The working clinical assumption is that benefits may last 1 to 3 years in good responders, after which some patients consider a repeat injection, which is priced as a new procedure. No reliable test predicts who will keep their improvement longer, so treat any clinic promise of a fixed duration with caution.

Am I a good candidate for this treatment?

Good candidates have KL Grade I to III osteoarthritis confirmed by X-ray or MRI, persistent knee pain despite 3 to 6 months of physical therapy and anti-inflammatory treatment, a BMI below 35, and realistic expectations. Poor candidates include people with Grade IV bone-on-bone arthritis and significant varus or valgus deformity, active infection, inflammatory arthritis, clotting disorders, active cancer, or immunosuppressive therapy. An orthopedic or sports medicine physician should confirm your grade first.